Patrick Boisseau

Patrick has joined MedTech Europe as of the 1st of September, as Director, EU Research & Innovation Partnership Policies. He will develop, promote, represent and lead the industry in EU Research and Innovation Partnerships or Programmes, working on European projects and interacting with the European Commission in the set-up, follow-up and coordination of European funding(ed) projects and any other similar EU initiatives.

Patrick will particularly lead MedTech Europe activities and representation in critical framework programmes such as Horizon 2020, Horizon Europe (2021 to 2027), EIT Health and others.

He was recently VP Europe at CEATech Healthcare Institute, based in Grenoble (France). He managed a significant number of EU collaborative projects, research infrastructures, coordination actions and networks of excellence. His scientific and technical expertise are in nanomedicine, drug delivery, medical imaging and innovative medical technologies. He is the [Patrick Boisseau] past Chairman of the European Technology Platform on Nanomedicine and the representative of MedTech Europe at the Inter-Association Task Force preparing the Public-Private Partnership on Health under Horizon Europe.

Patrick was educated as an agronomist at the National Agronomic Institute Paris-Grignon,  and as an engineer at ENGREF (École Nationale du Génie Rural des Eaux et des Forêts), together with a specialisation in DEA Nutrition Humaine at the University PARIS VI (France).

AI – Artificial Intelligence – sounds like another buzzword floating in the air of Brussels when we talk about future R&D priorities. There are many interpretations of what AI means, while some people are already grumbling that it’s just another fad. Personally, I believe that now is the time for practical examples of deployment of AI in medical practice. No more buzzwords, let’s get real! The European Commission is releasing three calls in its ICT Programme and Health Programme for 2019-2020. These topics call for collaborative projects, either fundamental or applied, classified in EC jargon as Research & Innovation Actions or Innovation Actions, respectively. In total, more than 100 M€ is being invested in AI for healthcare topics by the European Commission. The calls address: AI for Health Imaging (DT-TDS-05-2020, 13 Nov 2019, €35 million) AI for the smart hospital of the future (DT-ICT-12-2020, 20 April 2020, €40 million) AI for Genomics and Personalised Medicine (DT-TDS-04-2020, 20 April 2020, €35 million) I’ve had the opportunity to participate in the preparation of a proposal on AI for the smart hospital of the future. In order to strictly meet the requirements of the calls and the expected impacts – we all know that impact can make or break a proposal – we have assembled a very diverse group of partners comprising medtech companies, hospitals, health economists and, of course, AI companies. Finding a suitable AI partner was not so easy. I must confess that identifying a European Company with proven experience in AI in healthcare has been challenging because the field is so young. It also raises the question of European sovereignty in AI, especially in healthcare. Of course, inviting one of the big four tech companies – Google, Apple Facebook and Amazon (GAFAM) – would have been the first option for...
Patrick Boisseau will be a speaker at the MedTech Forum on 16/5. Find more about the programme here ! As European research and innovation funds extend their focus towards diagnostics, digital and medical technologies, medtech companies must be ready to engage. A major future EU public-private partnership in research and innovation is currently in gestation. I believe it could help to address some of the biggest challenges in modern healthcare – and its scope will be wide enough to welcome medical devices and diagnostics companies, large and small. Let’s consider some historical context. The EU research and innovation budget is significant. The Horizon 2020 programme, which ends next year, has a budget of around €80 billion. One of the key elements, as far as healthcare is concerns, has been the Innovative Medicines Initiative (IMI). This public-private partnership was funded by the European Commission and through in-kind contributions from pharmaceutical companies. In its first iteration, it had a total budget of €2 billion. The current incarnation which ends next year, has a budget of more than €3 billion. While IMI has, for more than 10 years, fostered collaboration and cooperation between pharmaceutical companies in unblocking bottlenecks in the medicines development pipeline, I expect the next big ‘PPP Health’ to go further. Modelled on the IMI structure as well as the ECSEL partnership for the micro-electronics sector, it will encompass pharma, biotech and medtech. This makes perfect sense: the solutions to the health challenges we face as a society do not lie in one industry – the future is patient-centred and integrated, with a significant role for digital technologies. I expect this approach to be welcomed by the medtech sector, particularly if it is accompanied by supports that will help start-ups and entrepreneurs tap into funds that may previously have seemed distant...